欢迎来到天天文库
浏览记录
ID:53726535
大小:257.75 KB
页数:3页
时间:2020-04-20
《洛铂联合伊立替康二线治疗小细胞肺癌的临床研究.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、2294重庆医学2014年6月第43卷第18期论著·临床研究洛铂联合伊立替康二线治疗小细胞肺癌的临床研究汪晓洁,寿涛,李丽华,缪坌,陈庆,陈雪丹(1.云南省第一人民医院肿瘤综合治疗中心/昆明理工大学附属医院,昆明650032;2.云南省红河州第三人民医院肿瘤内科,云南个旧661000)摘要:目的观察洛铂联合伊立替康与顺铂联合伊立替康二线治疗小细胞肺癌(SCLC)的疗效及毒副作用。方法对56例SCLC患者,均为一线依托泊苷联合顺铂方案治疗失败且在3~6个月内出现进展的患者,分为洛铂组(洛铂联合伊立替
2、康,n一30)和顺铂组(顺铂联合伊立替康,一26)。洛铂组:洛铂30mg/m静脉滴注,第1天;伊立替康65mg/m静脉滴注,第1、8天;顺铂组:顺铂25mg/m。静脉滴注,第2、3、4天;伊立替康65mg/m静脉滴注,第1、8天;两组均21d为1周期,化疗2周期以上者评价疗效,对两组患者近期疗效及毒副作用进行比较,并随访疾病进展时间(TTP)、生存期(Os)。结果洛铂组3O例,总有效率(RR)36.7,疾病控制率(DCR)66.7;顺铂组26例,RR34.6,DCR65.4,两组RR、DCR比较差
3、异无统计学意义(P>0.05)。洛铂组和顺铂组中位TTP分别为4.5个月、4.3个月,中位OS分别为8.5个月、8.4个月,两组比较差异无统计学意义(P>0.05)。洛铂组的主要毒副作用为骨髓抑制,顺铂组为消化道反应和骨髓抑制。洛铂组血小板减少Ⅲ~Ⅳ度较顺铂组明显,但差异无统计学意义(P>O.05);恶心、呕吐Ⅲ~Ⅳ度发生率顺铂组明显高于洛铂组,两组间差异有统计学意义(P4、观察。关键词:小细胞肺癌;洛铂;顺铂;伊立替康doi:10.3969/j.issn.167卜8348.2O14.18.012文献标识码:A文章编号:167卜8348(2014)18-229403ClinicalstudyofIobaplatinorcisplatincombinedwithirinotecanintreatingsmallcelllungcancerWangXiaoie,Shou了D,LiLihua,MiaoKun,C^enQing,ChenXuedan(1.Ontological5、ComprehensiveTherapyCenter,YunnanProvincialFirstPeopleHospital/AJl,iliatedHospitalofKunmingUniversityofScienceandTechnology,Kunming,Yunnan650032,China;2.DepartmentoJOncology,T『IrPeoplesHospitalofHonghePrefecture,Gejiu,Yunnan661000,China)Abstract:Objec6、tiveToobservetheeffectandadversereactionsoflobaplatinorcisplatincombinedwithirinotecan(CPT一11)inthesecondlinetreatmentofsmallcell1ungcancer(SCLC).Methods56casesofSCLCfailedinthefirstlinetreatmentschemeofetoposidecombinedwithcisplatinandprogressedwithi7、n3—6monthswererandomizedintothelobaplatingroup(1obaplatin+CPT一11)andthecisplatingroup(cisplatin+CPT一11).Thelobaplatingroup:lobaplatin30mg/m2byintravenousdripond1,andCPT一1165mg/mbyintravenousdripond1,8.Thecisplatingroup:cisplatin25mg/mbyintravenousdrip8、ond2,3,4,andCPTl165mg/mbyintravenousdripond1,8.Aftermorethan2cyclesofchemotherapy,thetherapeuticaleffectswereevaluated.Theshorttermeffectsandthetoxicandsideeffectswerecomparedbetweenthetwogroups.Furthermore,thetimetoprogression(TTP)andtheovera
4、观察。关键词:小细胞肺癌;洛铂;顺铂;伊立替康doi:10.3969/j.issn.167卜8348.2O14.18.012文献标识码:A文章编号:167卜8348(2014)18-229403ClinicalstudyofIobaplatinorcisplatincombinedwithirinotecanintreatingsmallcelllungcancerWangXiaoie,Shou了D,LiLihua,MiaoKun,C^enQing,ChenXuedan(1.Ontological
5、ComprehensiveTherapyCenter,YunnanProvincialFirstPeopleHospital/AJl,iliatedHospitalofKunmingUniversityofScienceandTechnology,Kunming,Yunnan650032,China;2.DepartmentoJOncology,T『IrPeoplesHospitalofHonghePrefecture,Gejiu,Yunnan661000,China)Abstract:Objec
6、tiveToobservetheeffectandadversereactionsoflobaplatinorcisplatincombinedwithirinotecan(CPT一11)inthesecondlinetreatmentofsmallcell1ungcancer(SCLC).Methods56casesofSCLCfailedinthefirstlinetreatmentschemeofetoposidecombinedwithcisplatinandprogressedwithi
7、n3—6monthswererandomizedintothelobaplatingroup(1obaplatin+CPT一11)andthecisplatingroup(cisplatin+CPT一11).Thelobaplatingroup:lobaplatin30mg/m2byintravenousdripond1,andCPT一1165mg/mbyintravenousdripond1,8.Thecisplatingroup:cisplatin25mg/mbyintravenousdrip
8、ond2,3,4,andCPTl165mg/mbyintravenousdripond1,8.Aftermorethan2cyclesofchemotherapy,thetherapeuticaleffectswereevaluated.Theshorttermeffectsandthetoxicandsideeffectswerecomparedbetweenthetwogroups.Furthermore,thetimetoprogression(TTP)andtheovera
此文档下载收益归作者所有